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Figure 1. Cytotoxic activity (mean and standard deviation) of lymphoid
leukemia-speciﬁc cord blood T cells expanded in cytokine cocktails IL-7, -12, &
- 15(n¼4) or IL-15 (n¼5) and IL-7 alone (n¼3)
Table 1
Dispose Reason N % of disposed
CBU/barcodes
(n¼77149)
Low TNCC 30815 39.9
Low Volume 17415 22.6
Placenta issue 7279 9.4
Not collected 5356 6.9
Maternal history problem 3817 4.9
Cord issue 3693 4.8
Low Viability 1404 1.8
Processing issues 1159 1.5
Cord clot 872 1.1
Maternal Sample Problem 750 1.0
Consent refused/withdrawn 567 0.7
Donate/research 553 0.7
Data Missing 546 0.7
Failed CBU Sterility 529 0.7
Subsequent Med Info 476 0.6
CBU Expired 364 0.5
Delivery complication 326 0.4
Training unit 307 0.4
Collection kit issue 301 0.4
Cryopreservation 251 0.3
Abnormality in baby 232 0.3
Potency/CFU 88 0.1
NRBC >50% 49 0.1
TOTAL 77149
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ated with IL-15 alone from previously CD3/CD28 expanded
CB T cells. While the cytotoxicity is comparable to those
primed/expanded by combinations of cytokines, the CTL
speciﬁcity is higher with IL-15 alone. Notably, the CTL activity
is not conﬁned to a single cellular subset and resides in the
TCRgd+ T cell.415
Why Do Umbilical Cord Blood Units Fail to Qualify for
Public Banking?
Jessica Wishnew 1, Stephen Wease 2, Jose Hernandez 3,
Kristin Page 1, Joanne Kurtzberg 1. 1 Pediatric Blood and
Marrow Transplant Program, Duke University Medical Center,
Durham, NC; 2 EMMES Corporation, Rockville, MD; 3 Carolinas
Cord Blood Bank, Duke University, Durham, NC
Background: The goal of the Carolinas Cord Blood Bank
(CCBB), a public cord blood (CB) bank, is to procure quality
cord blood units (CBU) for use in hematopoietic stem cell
transplantation. The banking process is comprised of donor
screening, collection, processing, cryopreservation and
testing. At each step, CBU eligibility is determined and units
not meeting speciﬁcations are discarded. We explored
reasons for CBU disposal to identify strategies to maximize
the number of successfully banked CBUs.
Study design and methods: The CCBB database was retro-
spectively analyzed to characterize and quantify reasons
CBUs were ineligible for banking. The reasons for discard
were collated, assigned to a step on a process chain and
assigned to a category. Speciﬁcations for banking included
a minimum volume of 40ml (to 2005) and 60ml (to present),
a preprocessing total nucleated cell count (TNCC) of
1x109cells and a post processing viability of >90%.
Results: From 1/1998-8/2012, 109,177 total CBU donors
registered in the database. Of these, 34% did not have CBUs
collected because of unavailable collection staff, placental/
cord damage or CB clot, among other reasons. A total of
71,618 CBUs were collected, 40,986 (57%) of which were
shipped to the processing lab. Twenty-two percent of the
CBUs sent for processing were subsequently discarded. Time
points for discard of collected CBUs were: 43% before pro-
cessing, 5% during processing and 7% after cryopreservation.
Reasons for disposal of 77,149 registrations or CBUs (Table 1)
included 40% for low TNCC, 23% for low volume, 2% for low
viability, and 0.7% for failed sterility.
Conclusion: We identiﬁed reasons for banking failures in
a large public CB bank. While small volumes/low TNCC rep-
resented the major reasons for failure of collected CBUs to bebanked, other factors inﬂuenced the failure to collect CBUs
from recruited volunteer donors. Improving MD and tech-
nician training to increase the volume of collections and
awareness of collection procedures in regards to placenta
and cord handling, as well as expanding program collection
hours, could impact the overall banking success. The ﬁnan-
cial impact of CBU losses will also be discussed.
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Introduction: Bronchiolitis Obliterans Syndrome (BOS) is
the manifestation of chronic GVHD (cGVHD) of the lung, it
affects approximately 10% of patients surviving one year post
transplantation (2), and the survival at 5 years is only about
10% (3). A timely diagnosis could improve the outcome of
this potentially fatal disease.
Methods: Using a lung transplantation scoring system (4),
we retrospectively evaluated 23 consecutive BOS patients to
determine whether an FEV1<90% and FEF25-75<75% (stage
BOS 0p), would have contributed to earlier detection. Addi-
tionally, we assessed IGF-1 (insulin growth factor 1) levels,
a proﬁbrogenic mediator (1), in serum samples of patients at
onset of cGVHD (n¼57), including 13/23 patients with
a diagnosis of BOS. A retrospective chart review was per-
formed to identify patients meeting the NIH Consensus
clinical deﬁnition of chronic GVHD of the lung (BOS) between
2007 and 2011. The criteria included: 1) FEV1 < .8 2) FEV1/
FVC < .75 and RV> 120% and 3)no evidence of infection on
most recent imaging or BAL at time of diagnosis. The dates
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recorded, and compared to the recorded date of BOS diag-
nosis. Fisher's exact test was applied to determine statistical
signiﬁcance where applicable.
Results: For all BOS patients, the mean time from trans-
plantation to diagnosis of BOS was 478 days (95% CI
357-599d) compared to amean time of 169 days (95% CI 100-
238d) when patients had either an FEV1<90% or FEF25-75
<75%. The mean difference was 298 days (95% CI 176-420d,
P ¼ .00003). Patients with cGVHD and no BOS had similar
decline in PFT in only 22/44 patients, compared to 100% of
those with BOS. Serum IGF-1 values were > 4,000 (25th
percentile) in 12 of 13 patients with BOS (P ¼ .04). Overall, 12
of 13 patients had biomarkers elevation prior to spirometric
diagnosis of BOS.
Conclusions: Application of the BOS 0-p criteria to HSCT
patients may identify patients at risk for BOS at an earlier
time point. The use of the IGF 1 as a serum biomarker may
also contribute to identify patients at risk, although further
studies are needed to investigate whether this marker can
differentiate between patients with BOS and those with
other lung diseases.417
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Haploidentical (HI) HSCT with low dose donor T-cell infusion
provides a survival advantage in tumor bearing mice when
compared to parent F1 or MHC-matched transplant models.
We suggest thatMHC difference in HI-HSCTgenerates early T-
cell clonal activation against the unshared MHC haplotype,
which eliminates residual tumor cells that express the
unsharedMHChaplotype.However, alteration inMHCantigen
expression is a signiﬁcant contributor to tumor escape from
graft-versus-tumor (GVT) activity. Recent haploidentical
transplant data revealed that uniparental disomy, the loss of
theHLAhaplotype, is a clinically relevantmechanismof tumor
escape that leads to post-transplant leukemia relapse. Murine
renal cell carcinoma, RENCA cell line normally expresses only
H2Kdas a MHC molecule. Therefore, in our haploidentical
transplant model, T cell clonal activity is usually restricted
against H2Kdmolecule only. For circumventing the single
haplotype expression of tumormodel, we transfected this cell
line with a H2Kbexpressing vector, pAcGFP-NeoR-H2Kb, and
generatedstable cloneswithG418 selection. The clone thathas
more than 95% H2Kbexpression used for in vivo experiments.
Both tumor cell lines, i.e. parental and transfected clone, had
similar in vivo tumor growth acceptance and growth rate. We
then used two different haploidentical donors that were tar-
geting different MHC haplotypes. Lethally irradiated B6D2F1
(H2Kb/d) mice were transplanted with T cell depleted bone
marrow(TCD-BM) fromeitherB6C3F1(H-2Kb/k) (singlehaplo-
1; SH1), or C3D2F1 (H2Kk/d) (single haplo 2; SH2) or both
donor mice with low-dose (1x105) T-cells. In some experi-
ments, animals were also injected either H2Kdor H2Kb/
d expressingRENCA-TGL cells for the evaluationofGVTactivity
Bone marrow (BM), spleens and thymi were harvested from
recipients of single and double HI-HSCT at day 35 and
showed similar cellularities. Interestingly, spleen and bonemarrow had similar chimerism from both donors in DH-
HSCT. There were no early transplant mortality, graft failure,
weight loss and GVHD scoring difference among the double
or single-haploidentical transplant recipients. In two other
sets of experiments, we followed the tumor growth and the
survival of tumor bearing mice after transplant. The recipi-
ents of DH-HSCT showed a better survival and GVT activity
than the recipients of SH-HSCT in RENCA-TGL (H2Kb/d)
bearing tumor model. These observations conﬁrmed that
MHC targeting plays a prominent role in tumor surveillance,
and immune targeting the unshared MHC haplotype with
haploidentical transplant induce remarkable survival
advantage.418
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Background: The most widely used mice model of chronic
graft-versus-host disease (cGvHD) is an MHC-matched bone
marrow transplantation model of sclerodermatous cGvHD. A
limitation of that model is that mortality is relatively low,
making difﬁcult to study the impact of potentially thera-
peutic compounds.
Aims: To develop a more severe model of cGVHD and to
assess the impact of Rapamycin administration in that
model.
Results: Lethally irradiated Balb/C mice were injected with
10x106 bone marrow cells and 70x106 splenocytes from
B10.D2 donor mice. Twenty-one days later, all mice devel-
oped cGvHD. For the severe model, donor B10.D2 mice were
injected with 0.5x106 splenocytes from Balb/C twenty-one
days before transplantation. All mice from the severe model
(n¼8) died a median of 32 days while 3 of 7 mice in the
classical model survived beyond day 52. Mean survival was
decreased in the severe model compared to the classical
model (32 days versus 37 days; p¼0.0185). Recipient mice in
the severe group experienced higher weight loss, hair loss
and skin ﬁbrosis. Numbers of T lymphocytes (251.9  151.4
versus 626.3  532.8; p¼0.0004) and CD4+ T cells (61.57 
41.93 versus 125.0  14.39; p¼0.0008) per microliter of
blood at day 21 were lower in the severe group than in the
classical model. Moreover, number of regulatory T cells
(Tregs) was decreased in the severe model (0.9870  0.8864
versus 7.979  6.753; p¼0.0062).
We then investigated whether rapamycin administration
could prevent GVHD in the severe model. All (n¼8) mice
treated with PBS (placebo) died a median of 32 days after
transplantation, while 6 of 8 mice given 1mg/kg/day i.p.
rapamycin survived beyond day 52 (p¼0.0012). Number of
Tregs/ml was higher at day 21 in rapamycin-treatedmice than
in mice given PBS (3.532  1.195 versus 1.958  0.8864;
p¼0.0796). Moreover, number of naïve CD4+T (7.798  4.192
versus 25.71  5.185; p¼ 0.0276), effector memory CD4+ T
cells (EMT) (40.50  3.180 versus 25.17  7.881; p¼ 0.0392)
and central memory CD4+ T cells (CMT) (53.58 3.180 versus
26.29  7.881; p¼ 0.0060) were higher in rapamycin mice.
Finally, proliferation of EMT (assessed by ﬂow cytometry
using Ki-67) (34.70%  4.084 versus 30.80%  2.003;
p¼0.0221) and CMT (33.25%  4.084 versus 27.50%  2.003;
p¼0.0183) was higher in PBS than in rapamycin mice.
